Xylazine-BSA Conjugate
- -
- -
BackgroundXylazine is a potent alpha-2 adrenergic agonist that was initially developed as a veterinary sedative and analgesic medication. Xylazine was not approved for human use and has been increasingly found in samples of illicit drugs like fentanyl. The increase in the detection of xylazine mixed with fentanyl has corresponded with an increase in overdose deaths. In 2023, fentanyl mixed with xylazine was declared an emerging threat by the White House’s Office of National Drug Control Policy. Protein DetailsFormat BSA Conjugated Purity ≥90% Product Concentration 5.0 mg/mL State of Matter Liquid Formulation Formulated in 0.015 M phosphate buffered saline (0.15M NaCl) and contains 0.05% sodium azide. Storage and Stability This product is stable when stored at 2-8°C. Do not freeze. Country of Origin USA Shipping 2-8°C Wet Ice Regulatory Status Research Use Only Applications and Recommended Usage ? (Quality Tested by Leinco) ELISA, Lateral Flow References & Citations1. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Link Technical Protocols Lateral Flow Certificate of AnalysisIMPORTANT Use lot specific datasheet for all technical information pertaining to this recombinant protein. |
Products are for research use only. Not for use in diagnostic or therapeutic procedures.
